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EDITORIAL REVIEW
Hypercoagulability, renal vein thrombosis, and other
thrombotic complications of nephrotic syndrome
Thromboembolic phenomena, as well as renal vein
thrombosis, remain one of the most serious complications of
patients with nephrotic syndrome. In them, expecially in those
with membranous nephropathy, recent studies have shown an
incidence of renal vein thrombosis that ranges from 5 to 62%,
with an overall incidence of 35% (Table 1). Furthermore, the
incidence of thromboembolic complications other than renal
vein thrombosis in the nephrotic patient ranges from 8.5 to 44%,
with an overall incidence of 20% (Table 2). Pulmonary embo-
lism is the most frequent and serious complication, accounting
for 8%.
Although the occurrence of thrombosis has been recognized
for over a century, it was Addis [1] in 1948 who drew attention
to the high incidence of these complications. At that time, while
discussing complications in patients with the nephrotic syn-
drome, he said, "The first is the liability of these patients to
contract sudden and rapidly extending infections," and, a
paragraph later, he commented, "The second is the quite
frequent occurrence of venous thrombosis. For some curious
reason, this has not, so far as we know, been described."
Interestingly, despite Addis' clinical description, the cumula-
tive risk of these complications has been recognized only
recently. The advent of corticosteroid treatment for nephrotic
patients may have increased the incidence of thrombosis further
[21, but it was through the introduction of penicillin that survival
of nephrotic patients improved significantly, which may have
led to the increased incidence and/or recognition of thrombotic
episodes. Finally, another contributing factor may be the com-
mon use of diuretics, such as thiazides or furosemide, in the
nephrotic patient. These agents, with their volume-depleting
effects, lead to hemoconcentration, which favors the develop-
ment of thrombotic complications.
I believe that the risk of thromboembolic complications in
patients with the nephrotic syndrome is among the highest
encountered in medicine. Therefore, the pathophysiology of a
hypercoagulable state observed in the nephrotic syndrome will
be discussed first and then data of various recent investigators
regarding thromboembolic complications and renal vein
thrombosis will be reviewed.
Hypercoagulability
Recently, it has been established that the nephrotic syndrome
is associated with a hypercoagulable state; however, the role of
that state as a pathogenetic factor that leads to the high
incidence of thromboembolic complications observed in ne-
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phrotic patients has not been determined conclusively, espe-
cially since hypercoagulability is a hypothetical concept that
implies that pre-thrombotic changes can be detected in the
blood and that such changes are important in the development
of thromboembolic complications. Furthermore, it has been
assumed that changes in blood coagulation factors may be used
to predict thromboembolic complications. Unfortunately, on
this point the literature is confusing. A causal relationship
between the hypercoagulable state and the subsequent devel-
opment of thrombosis in the nephrotic syndrome has not been
established, but, nevertheless, profound clotting factor abnor-
malities have been observed in the nephrotic syndrome.
There are five major functional classes of coagulation com-
ponents: a) zymogens (Factors II, V, VII, IX, X, XI, and XII),
which are activated to enzymes, and co-factors (Factors V and
VIII), which accelerate the rate of conversion of zymogens; b)
fibrinogen; c) the fibrinolytic system; d) clotting inhibitors; and
e) components of platelet reaction and thrombogenesis.
Alterations in zymogens and co-factors
Studies of plasma procoagulant activity have shown, in
general, a decrease in levels of Factors IX, XI, and XII [3—11].
The low levels of these proteins appear to be due, in part, to
their urinary loss due to their small molecular size rather than to
impaired protein synthesis. This is relevant especially in Factor
XII, which plays an essential role in several important
proteolytic pathways. Its constant activation leads not only to
the initiation of the increased coagulation pathways, but also to
the triggering of the fibrinolytic and kallikrein-kinin systems.
However, urinary loss of these factors has not been observed
by all investigators. Thus, Factor IX procoagulant activity has
been found to be more variable; it has been observed to be
within the normal range [7, 8]. A number of cases with
deficiency of Factor IX have been observed since the original
description by Handley and Lawrence [3, 4, 12]. However, in a
recent study of 21 adult nephrotic patients, Factor IX was
increased significantly and no instances of Factor IX deficiency
were observed [13]. Although a correlation between urinary and
plasma Factor IX levels and the degree of proteinuria has been
noted by some observers, this has not been confirmed by
others. An increase in the levels of Factor II and combined
Factors VII and X has been described also [14]. In general,
most of these zymogen abnormalities tend to normalize with
clinical remission of the nephrotic syndrome [3].
Increased levels of co-factors (Factors V and VIII) have been
observed in the nephrotic syndrome [14—16]. Thus, Kanfer et al
reported a Factor VIII activity exceeding 200% in 22 of 57
nephrotic patients [15]. A number of studies have observed a
correlation between the increase in Factor V and Factor VIII
with a fall in serum albumin [6, 15, 16]. It appears that these
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Table 1. Prospective studies evaluating the incidence of RVT in
patients with nephrotic syndrome and membranous nephropathy
Investigator
N with
RVT in NS
mci-
dence
%
N with
RVT in MGN
mci-
dence
%
Bennett et al [1101 5/10 50
Noel eta! [111] 5/16 33
Wagoner et al [113] 14/27 50
Cameron etal[1l4] 2/15 13
Pohl eta! [112] 1/54 2 1/20 5
Liach et a! [109] 33/151 26 20/69 29
Monteon eta! [117] 15/53 28 15/24 62
Vosnides eta! [115] 7/44 16 5/30 17
Velasquez and
Garcia [116] 8/19 42 3/5 60
a Modified from Llach [1181.
Abbreviations are: N, number of patients; RVT, renal vein throm-
bosis; NS, nephrotic syndrome; MGN, membranous nephropathy.
changes result from increased synthesis of this protein by the
liver; apparently, the mitochondria of the liver cells are the final
sites of production of most of these proteins [17]. A decrease in
plasma oncotic pressure and/or a decrease in serum albumin
concentration may be sensed by the cells, which, in turn,
respond with an increased production of different proteins.
Factors V and VIII have not been found in the urine of the
nephrotic patients; this may be due to the large size of these
molecules.
During the earlier description of the hypercoagulable state,
one hypothesis held that an increase of co-factors may lead to
hypercoagulability and may explain the high incidence of
thrombosis. However, two important points must be made
regarding this hypothesis. First, all of these factors are present
in great excess in the circulation normally, with only a small
amount of any given factor being activated during thrombus
formation in vivo. Thus, it seems unlikely that high levels of any
of the zymogens would lead to thrombosis, or that a reduced
level of some coagulation factor would be a sensitive marker of
the presence of thrombosis. Second, there is no available
evidence suggesting that the increased levels of co-factors may
lead to thromboembolic phenomena. Usually, high levels of
co-factors are present during an acute inflammatory response
since they are acute-phase reactant proteins; these factors are
increased in pregnancy also, and there is no current evidence
suggesting that any of these conditions are associated with
increased risk of thrombosis.
Alterations in fibrinogen and conversion offibrinogen to
fibrin
An elevation of the plasma fibrinogen levels is a consistent
and significant abnormality observed in the nephrotic patients
[14—16, 181. Using 1311-labeled fibrinogen, Takeda and Chen
have observed that the rate of fibrinogen catabolism is normal
and that the observed increase in plasma fibrinogen is due to an
increased synthesis that is proportional to the urinary protein
loss [19]. Thus, Kanfer et al studied 40 nephrotic patients; 35
had hyperfibrinogenemia, with a mean plasma fibrinogen for the
whole group of 630 mgldl [151. In addition, there is a significant
direct correlation between fibrinogen and cholesterol levels,
and both are related inversely to the levels of serum albumin
[15—16]. The levels of fibrinogen in nephrotic patients may be as
high as 1 g/dl and have been shown to alter plasma viscosity
considerably [18]. Thus, increased plasma fibrinogen concen-
tration reflects its increased hepatic synthesis; contracted intra-
vascular distribution may be present, and there is a normal
degradation rate of fibrinogen in the nephrotic patient. It is
likely that the high fibrinogen level plays an important role in
the hypercoagulable state. Finally, an abnormality in the fibrin-
ogen molecule, as evidenced by prolonged reptilase and throm-
bin time, has been observed in membranous nephropathy [20].
The significance of this abnormality is not clear.
Alterations in the fibrinolytic system
The basic function of the fibrinolytic system is the conversion
of a beta globulin, plasminogen, by plasminogen activators into
an active serum protease, plasmin. This system is modulated by
four inhibitors of both plasminogen and plasmin. These inhibi-
tors include an alpha-2 macroglobulin, alpha-l antitrypsin,
antithrombin III, and C1 inactivator. Several clinical studies
have reported an association between defective fibrinolysis and
thrombosis; the association includes patients taking oral con-
traceptives [21], pregnancy [221, post-operative states [23],
malignant diseases [24], obesity [25], and the nephrotic syn-
drome [26]. The data about fibrinolytic abnormalities reported
in nephrotic patients are conflicting. In general, the plasma
plasminogen concentration is decreased [26—28]. This decre-
ment has been correlated with the low serum albumin and the
magnitude of the proteinuria [29—3 11. In addition, antiplasmin
activity (alpha-i antitrypsin) has been reported to be low in
these patients also [16]. A correlation between plasma albumin,
plasma plasminogen, and alpha-i antitrypsin suggests that the
urinary loss of plasminogen, together with that of albumin, may
be responsible for these low levels [27]. Jacobsson has observed
increased antiplasmin activity (alpha-2 macroglobulin fraction)
in the nephrotic syndrome [32]; however, it is likely that the
fibrinolytic activity, as determined by measurement of the
alpha-2 macroglobulin fraction, is small compared to those
estimates that measure total plasma antiplasmin activity [16].
Recently, a fifth inhibitor has been demonstrated to limit the
proteolytic activity of plasmin. This is an alpha-2 antiplasmin
and has been characterized as the primary plasmin inhibitor,
binding instantaneously any plasmin formed [33, 34]. It is
present in human plasma at a concentration of approximately 60
g/ml [33, 35]. In a dose-dependent way, alpha-2 antiplasmin
interferes with the binding of plasminogen fibrins and instanta-
neously becomes cross-linked to forming fibrin solubilizing
factors [36, 371. Thus, any thrombi formed in the presence of an
elevated level of alpha-2 antiplasmin would not only contain
less plasminogen for conversion for plasmin, but also would be
more resistant to lysis [37].
Recently, Du et al have demonstrated increased levels of
alpha-2 antiplasmin in nephrotic patients [38]. They studied the
fibrinolytic system in 44 patients with nephrotic syndrome, 14
of whom demonstrated renal vein thrombosis (RVT). In both
subgroups, although the level of total fibrinolytic activity was
normal, the levels of alpha-2 antiplasmin were increased. It was
elevated significantly in 13 of 14 plasma samples from patients
with RVT, but in only 12 of 30 from those without evidence of
RVT. These data seem to suggest that an increased level of the
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Table 2. Summary of published studies evaluating thromboembolic complications in the nephrotic syndromea
Investigator
N
studied
N with
thrombosis
Venous Arterial
Total other
episodesRenal Pulmonary DVT Coronary Cerebral Peripheral
Andrassy et a! [18] 84 30 (38%) 6 7 23 3 1 3 37 (44%)
Kauffman et al [661 48 9 (19%) 4 4 3 — — 1 8 (17%)
Kanfer et a! [15] 45 13 (29%) 3 3 6 — 2 1 12 (27%)
Pohl et al [112] 59 5 (10%) 1 2 3 — — — 5 (8.5%)
Kuhlmann et al [100] 17 4 (23%) 1 2 1 — — — 3 (17%)
Velasquez and Garcia [116] 19 8 (42%) 8 1 2 — — — 3 (16%)
Llach et a! [109] 151 41(26%) 33 18 3 2 2 1 26 (17%)
Kendall et al [14] 35 4 (23%) 1 3 — 1 1 1 6 (17%)
a Modified from Liach et al [140].
Abbreviations are: N, number of patients; DVT, deep vein thrombosis; RVT, renal vein thrombosis.
main inhibitor of plasmin, alpha-2 antiplasmin, could be a
reliable marker for a pre-disposition to renal vein thrombosis.
Various techniques have been used to detect end products of
fibrinolysis, including measurement of fibrinopeptide A and B,
which are cleaved from fibrinogen by thrombin, circulating
complexes of fibrin monomers, and fibrin degradation products.
Various radioimmunoassays for fibrinopeptide A have been
developed recently [39, 40]. Patients with evidence of intravas-
cular thrombosis have shown elevated levels of fibrinopeptide
A [411. It has been demonstrated also that fibrinopeptide A is
generated more rapidly in vitro in plasma obtained from pa-
tients with pulmonary embolism, systemic lupus erythemato-
sus, or disseminated intravascular thrombosis than in plasma
from normal control subjects [41]. These observations provide
convincing evidence for the presence of activated coagulation
factors in the circulation and that the blood of these patients
truly is hypercoagulable in vivo. Although these tests were
promising initially, it was thought that they lacked the speci-
ficity and sensitivity to be used clinically, primarily because of
the high incidence of false positive results in patients with
infections or in those who have undergone recent surgery [42].
In addition, until recently, the measurement of fibrinopeptides
was exclusive to specialized laboratories. In the last few years,
with the availability of commercial kits for fibrinopeptide A
determination, extensive studies have outlined major applica-
tions of this test [43]. The measurement of fibrinopeptide A is a
sensitive marker of patients with deep vein thrombosis, pulmo-
nary embolism, pregnancy associated with hypertension, pre-
eclampsia, and myocardial infarction [44—46]. In patients with
suspected myocardial infarction, high levels of fibrinopeptide A
correlated with the severity of infarction [47]. Persistently high
levels of fibrinopeptide A usually are associated with poor
prognosis in patients with advanced cancer [48]. Although no
specific data are available on the use of fibrinopeptide A in the
nephrotic patient, it appears to be a promising tool for the
detection of thrombosis in nephrotic patients.
A number of investigators have demonstrated soluble poly-
mers of fibrinogen-derived species in the blood of patients with
thromboembolic disease [49—51]. These complexes are made up
of fibrin monomers polymerized with fibrinogen, with other
fibrin monomers, or with fibrin degradation products. Fibrin
monomer complexes have been found in patients with throm-
boembolic disease [52], and they are found more frequently
than normal in women taking oral contraceptives containing
estrogen and in patients with coronary artery disease [53, 54].
An increase in the serum concentration of fibrinogen degra-
dation products (FDP) is not observed commonly in nephrotic
patients, but has been observed in the urine of patients with
glomerulonephritis [55]. Some nephrotic patients have been
found to have increased urinary levels of fibrin degradation
products [56]. However, these findings should not be taken as
definite evidence of increased fibrinolysis in the systemic or
renal vasculature, because, in patients with non-selective pro-
teinuria, fibrinogen is filtered in the glomerulus and may un-
dergo proteolytic degradation by protease. Indeed, gel chroma-
tography shows clearly that material interpreted as FDP in the
past actually is filtered fibrinogen that is degraded in the tubules
[18, 57].
Alterations in coagulation inhibitors
The components of the coagulation system exist in the
circulation as zymogens, and they are cleaved to form
proteolytic enzymes. Activated clotting factors are inhibited by
naturally occurring coagulation inhibitors [4—5]. They include
an alpha-2 globulin known as antithrombin III (AT-Ill), alpha-2
macroglobulins, alpha-l antitrypsin, and C1 inactivator. AT-Ill
appears to be the most important of these coagulation inhibi-
tors. It is an alpha-2 globulin and is the main inhibitor of
thrombin [58]. It also inhibits activated Factors XII, IX, X, XI,
and plasmin [59, 60]. The rate of inhibition of these enzymes by
AT-Ill is increased markedly in the presence of heparin [61].
Alpha-I antitrypsin inhibits a number of coagulation enzymes,
but with a low affinity; therefore, it may not be important
clinically [62]. Alpha-2 macroglobulin inhibits only thrombin,
and, during thrombosis, the level of this globulin remains
unchanged [631. C1 inactivator inhibits other enzymes, but is
not important in the coagulation system [62]. The importance of
AT-Ill has been appreciated only recently. In families with an
inherited deficiency of AT-Ill, two-thirds of the members with
serum levels around 5% of normal develop thrombosis [64, 65}.
An increased incidence of thromboembolic complications gen-
erally is observed when antithrombin levels are below 75% of
normal.
Recently, Kauffman et al have studied the AT-Ill levels in 48
patients with proteinuria and its relationship with the occur-
rence of thromboembolic phenomena [66]. Nine have evidence
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of thrombosis, including four with renal vein thrombosis. In
eight of these nine patients, the serum AT-Ill levels were below
70%. There was a significant correlation between AT-Ill con-
centration and the urine protein excretion. Only 6 of the 32
patients who excreted less than 10 g/24 hr had AT-Ill levels
below 85%, whereas 13 of 16 patients with proteinuria higher
than 10 g/24 hr showed depressed AT-Ill levels, Since the
molecular weight of AT-Ill is relatively low, excretion in the
urine will be expected in patients with proteinuria. Because of
the similar molecular weight, the renal clearances of AT-Ill and
albumin were compared. A significant correlation was found
between the concentration of these two proteins (P < 0.001). In
addition, there was a significant correlation between the renal
clearance and the degree of AT-Ill deficiency. It was concluded
that thrombosis in nephrotic patients may be associated with
the deficiency of AT-Ill due to increased urinary loss, and low
levels of AT-Ill may be insufficient to inactivate procoagulant
factors, resulting in the development of thrombosis. These
results are in apparent conflict with studies showing normal or
increased antithrombin activity in nephrotic children [15, 161;
however, this may have been due to the non-specific in vitro
inhibition of thrombin by alpha-2 globulin and alpha-I
antitrypsin (two other clotting inhibitors), and the apparent
increment in AT-Ill activity may not have reflected a true
increase in AT-Ill levels. In addition, AT-Ill deficiency was
reported by other investigators generally in association with
serum albumin of less than 2 g/dl [18, 66, 671, while in the earlier
studies, only a few patients had severe hypoalbuminemia [15,
16]. The observation of Boneu et al in 28 nephrotic children is
noteworthy [68]. They observed a dramatic reduction of AT-Ill
levels that was counterbalanced by an increase in the alpha-2
macroglobulin fraction. The authors speculated that, in chil-
dren, this compensatory mechanism may explain the lower
incidence of thrombosis when compared with adult nephrotics.
Recently, Panicucci et al have reported normal levels of AT-Ill
despite high urinary AT-Ill levels [69]. They suggested that
increased AT-Ill synthesis compensated for its renal loss.
Later, Vaziri et al observed a significant decrease in AT-Ill
plasma concentration and activity in 20 nephrotic patients when
compared with normal subjects [70]. Also, substantial urinary
losses of AT-Ill were demonstrated in the nephrotic patients.
Thus, although the rate of synthesis and degradation of AT-Ill
and its distribution has not been determined, it is likely that
renal losses of AT-Ill in nephrotic patients contribute to AT-Ill
deficiency. It is possible that the danger of thromboembolic
phenomena arises with sudden changes in the activity of the
renal disease, resulting in abrupt renal losses of AT-Ill, while
hepatic synthesis of AT-Ill has not yet increased. An interest-
ing observation is the increase in AT-Ill levels in nephrotic
patients after steroid therapy [71].
Recently, important data about the role of coagulation inhib-
itors in the development of thrombosis have been reported.
Protein C and protein S have been identified as potent
anticoagulants. Protein C is a vitamin K-dependent serum
protease zymogen, which is homologous with other known
vitamin K-dependent serum protease [72]. This protein is an
anticoagulant since it prolongs the clotting time of plasma in
various clotting assays [73]. Bovine protein C has been well
recognized and characterized biochemically and functionally
[74, 75], while less is known about the human molecule. This
protein is a glycoprotein of 62,000 molecular weight that circu-
lates in human plasma at a concentration of about 4 g/ml [76].
It consists of a heavy chain of 41,000 daltons and a light chain
of 21,000 daltons which are joined by a single disulfide bridge.
Protein C inactivates the coagulation Factors V and VIII [77].
The rate of inactivation of these co-factors in plasma is rapid,
since greater than 80% of activity is destroyed in 3 mm by 3
g/ml of activated protein C. Human protein C must be
activated proteolytically to function as an anticoagulant [78]. It
can be activated by several proteolytic enzymes, such as Factor
X, activator of Russell viper venom, trypsin, or thrombin
[78—80]. The pathophysiological relationship of protein C with
Factors V and VIII was established when it was shown that
plasma from patients suffering from an inherited combined
deficiency of Factor VIII and V are missing the inhibitor of
activated protein C [811. The clinical role of protein C as an
important antithrombotic regulatory molecule has been demon-
strated recently by identifying a familial thrombotic disease that
is associated with an inherited partial deficiency of protein C
[82]. Thus, families with a deficiency in plasma protein C have
recurrent thrombosis. It appears that protein C levels below
50% result in thrombosis. While antithrombin III appears to be
a major regulatory protein in limiting the activity of
procoagulant plasma enzymes, activated protein C may repre-
sent a major regulatory protein limiting the activity of activated
procoagulant factors (Factors V and VIII). In this respect, the
anticoagulant properties of activated protein C and antithrom-
bin III are complementary.
It is too early to know whether a deficiency of protein C
exists in patients with nephrotic syndrome; however, these
studies make further investigations promising.
Recently, the rate of inactivation of Factor V by activated
protein C has been found to be stimulated by another vitamin
K-dependent protein, protein S [83]. Protein S has no effect
upon Factor V activity in the absence of activated protein C,
indicating that it is not a protease. In a protein S-deficient
plasma, the anticoagulant activity of activated protein C is
reduced significantly and, when protein S is added, the activity
of protein C is restored. It appears that the complex between
protein S and activated protein C is formed only in the presence
of phospholipids [84]. Since protein S is required for the
expression of the anticoagulant activity of activated protein C,
it is not surprising that recently a deficiency of protein S has
been found to predispose to recurrent thrombosis [851. Thus,
Comp and Esmon have identified six unrelated persons with
severe, recurrent venous thrombosis who were deficient in
protein S, with levels between 15 and 37% [85]. However, they
noted that not everyone who is partially deficient in this protein
will, in fact, develop thrombosis. Therefore, which persons
deficient in protein C will develop thromboembolic phenomena
may depend on a number of other factors. Functional levels of
protein S in patients with nephrotic syndrome are not yet
available.
In summary, available evidence suggests that AT-Ill deficiency
plays an important role in the development of thrombosis. In addition
to AT-Ill, proteins C and S may be of diagnostic value in the
hypercoagulability of the nephrotic syndrome. Longitudinal data are
needed in nephrotic patients, especially for those patients with
thromboembolic complications.
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Alterations in platelet function and components of platelet
reaction in thrombogenesis
The role of platelets in thrombogenesis is well accepted.
Platelets adhere to the surface, and they release ADP and
aggregate. At the time they are exposed to aggregating agents,
they change shape and release products that facilitate the
interaction of coagulation factors and accelerate thrombin for-
mation. Substances that may induce release of stored granules
from platelets include ADP, thrombin, collagen, arachidonic
acid, immune complexes, epinephrine, and vasopressin. Vari-
ous abnormalities in platelet function, as well as in the release
of various proteins by the platelets, have been linked to
increased thromboembolic phenomena. However, available
data are not conclusive at this time. Thus, there is no definite
evidence that shows that even thrombocytosis or hyperactive
platelets, if they exist, predispose to thrombosis. Various
attempts have been made to develop assays that measure
released proteins as a part of platelet function, which may be
useful in the diagnosis of a pre-thrombotic state. A number of
investigators have reported high levels of platelet Factor 4 in
venous and arterial thrombosis [86, 871. A radioimmunoassay
has been developed for a platelet-release-specific protein, B-
thromboglobulin. This protein is released upon platelet aggre-
gation and has been found to be correlated negatively with
indices of platelet survival. Preliminary studies have shown
high levels of this protein in patients with pulmonary embolism
[88].
Thrombocytosis is often present in the nephrotic patient
[14—15]. Nevertheless, normal platelet levels have been re-
ported [68, 89]. An increase in ADP- and collagen-induced
platelet aggregation has been observed in vitro in all 11 of 14
children with nephrotic syndrome [901, and the hyperaggreg-
ability could be reversed if the urinary protein was added,
suggesting that the urinary loss of some factor inhibited platelet
aggregation. In the adult nephrotic patient, an increase in
platelet aggregation with ADP and collagen but not with epi-
nephrine has been observed [18]. Also, there is a significant
correlation between the platelet abnormality and the degree of
proteinuria. A spontaneous increase in platelet aggregation has
been observed in these patients, with a significant correlation
between the platelet aggregation and plasma cholesterol levels
[Andrassy, Depperman, and Walter, personal communication].
Hyperlipidemia is known to affect platelet function and may
increase platelet aggregation in the nephrotic patient. Clinical
and experimental data in patients with familial type II
hyperlipoproteinemia suggest that the serum lipoprotein con-
centration may affect platelet reactivity by altering the platelet
membrane lipid composition, and that hypercholesterolemia
increases platelet sensitivity for aggregating agents in vitro [91,
92]. In nephrotic patients, platelet aggregation is increased to a
level similar to that observed in patients with type II
hyperlipoproteinemia, and their platelets are found to be par-
ticularly sensitive to collagen [18]. Furthermore, it has been
shown that release of arachidonic acid is an important event in
platelet aggregation [59]. The conversion of arachidonic acid
released from platelet phospholipids or elsewhere into metabo-
lites that aggregate platelets is known to be regulated by
albumin [93, 94]. Hypothetically, in the presence of
hypoalbuminemia in nephrotic patients, arachidonic acid may
be metabolized into platelet-aggregating substances, such as
endoperoxides and thromboxane A2. In line with this hypothe-
sis, the degree of platelet function abnormalities correlates with
the degree of hypoalbuminemia and the severity of the protein-
uria [90]. Remuzzi et al have observed that the low plasma
albumin concentration in nephrotic patients may be associated
with hypersensitivity to platelet aggregation induced in vitro by
arachidonic acid, and the hypersensitivity is corrected with an
increase in serum albumin concentration [95]. This is supported
further by the observation that the threshold concentration of
ADP necessary to induce platelet aggregation is low and can be
normalized in vitro by adding albumin to the blood [54]. In
addition, platelets of patients with hypercholesterolemia are
refractory to adenylate cyclase stimulation by PGE1 [96].
Similar observations have been made by Kreusser et al in
nephrotic patients [97]. They have demonstrated a lesser incre-
ment in platelet cyclic AMP content after PGE1 stimulation in
nephrotic patients when compared with normal subjects. This
promotes a milieu conducive to increased platelet aggregation
and vasoconstriction.
The levels of p-thromboglobulin, a specific protein released
by platelets upon aggregation, are elevated significantly in
nephrotic patients and return to normal with clinical remission
[98]. However, normal /3-thromboglobulin levels have been
reported in nephrotic patients also [99]. Plasma Factor 4,
another protein released by platelets, has been found to be
normal in these patients [99]. Recently the levels of
f3-thromboglobulin and platelet aggregation of 17 nephrotic
patients with and without thromboembolic complications have
been studied [100]. Thromboembolic complications occurred
only in the four patients with serum albumin below 2 gldl and
with elevated /3-thromboglobulin levels. In addition, there was
an abnormal platelet aggregation, assessed by estimating c-2
angle values derived from platelet aggregation curves in the four
patients with thrombosis, where patients with thrombosis
showed normal -2 angle values. Also, the decrease in serum
albumin concentration showed an inverse correlation relation-
ship with a-2 angle values. These data suggest, again, a regu-
latory role of albumin in platelet aggregation.
In summary, the hypercoagulable state of the nephrotic
syndrome is characterized by low zymogen factors, a marked
increase in co-factors (Factors V and VIII), an increase in
plasma fibrinogen levels, a decrease in the levels of antithrom-
bin III and antiplasmin activity, thrombocytosis, increased
platelet aggregation, and an increase in levels of
f3-thromboglobulin. The high fibrinogen levels, by altering
plasma viscosity, may be important in the hypercoagulable
state. The available data about fibrinolytic activity do not make
it clear, but increased levels of alpha-2 antiplasmin may be a
reliable marker of thrombosis. A convincing relationship has
been found between low antithrombin III levels and
thrombosis. Protein C and protein S should be investigated in
nephrotic patients. It is likely also that increased platelet
aggregation may be an important factor in the hypercoagulabil-
ity of the nephrotic syndrome, and that the increased levels of
/3-thromboglobulin may be a reliable marker of platelet aggre-
gation. In addition, the release of arachidonic acid may play a
key role in the increased platelet aggregability observed in
nephrotic patients, and the levels of serum albumin may be
important in the platelet aggregation. At present, it is difficult to
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implicate the hypercoagulability in nephrotic patients as a
causal factor in the increased incidence of thromboembolic
complications, and it must be emphasized that the majority of
these studies are hematological and without clinical correlation
with thromboembolic complications. In addition, these studies
lack a longitudinal approach to patients with clotting abnormal-
ities that may lead to thromboembolic complications, and such
an approach is needed to define the pre-thrombotic state of the
nephrotic syndrome. As a result, the combination of certain
tests may lead to the identification of the nephrotic patient at
high risk for thromboembolic complications, but certain criteria
for the evaluation of this problem are advisable. First, the
clotting abnormality described in the nephrotic patient should
be specific for thrombosis. Second, the correlation of the
clotting abnormalities thought to be responsible for the throm-
boembolic complications should be monitored by specific blood
tests reflecting the thrombosis. Third, improvements of the
thromboembolic complications should follow the correction of
blood clotting abnormalities. Following these criteria may clar-
ify the role of hypercoagulability in the thromboembolic com-
plications experienced by nephrotic patients.
Renal vein thrombosis
For many years, it was thought that renal vein thrombosis
(RVT) was the cause of the nephrotic syndrome—a belief that is
no longer considered true. Several lines of evidence have
questioned this hypothesis seriously. First, experimentally in-
duced RVT causes only mild proteinuria, and the renal histol-
ogy and immunofluorescent findings in these cases do not
resemble those of membranous nephropathy [101, 102]. Sec-
ond, RVT in the absence of the nephrotic syndrome has been
reported in the surgical literature [103, 104]. Moreover, in
autopsy studies of patients with RVT, nephrotic syndrome was
present ante mortem only in a few patients [105]. Third, most
patients with RVT and nephrotic syndrome who have been
subjected to renal morphological studies have exhibited an
identifiable glomerulopathy that was responsible for the ne-
phrotic syndrome [106]. Finally, it has been shown recently that
RVT occurs after the onset of the nephrotic syndrome [107,
108]. It is likely that the hypercoagulable state, together with
the type of renal disease, may be important pathogenic factors
in the genesis of RVT, as well as other thromobembolic
phenomena.
A review of the etiology and type of nephropathy associated
with RVT may help us to understand the relationship between
thromboembolic complications and the nephrotic syndrome.
The incidence of RVT in the nephrotic syndrome, although
variable, has been found to be significant. A review of all our
cases with nephrotic syndrome is shown in Table 3. Of 151
patients with the syndrome, 33 had RVT and, of these, 20 had
membranous nephropathy and 6 had membranoproliferative
glomerulonephritis. This high incidence of membranous
nephropathy has been reported by other investigators also
[109—117]. The incidence of RVT in the nephrotic syndrome in
general and in membranous nephropathy is shown in Table 2.
This table includes data only from prospective studies evaluat-
ing nephrotic patients undergoing routine renal venograms,
regardless of the presence or absence of symptoms suggestive
of RVT. It can be appreciated that the overall incidence of RVT
in both nephrotic syndrome and membranous nephropathy is
Table 3. Etiology of the nephrotic syndrome in 151 casesa
With Without
renal vein renal vein
thrombosis thrombosis Total
Renal diagnosis N N N
Membranous nephropathy 20 49 69
Membranoproliferative
glomerulonephritis 6 21 27
Lipoid nephrosis 2 8 10
Rapidly progressive gb-
merulonephritis 1 1 2
Amyboidosis 1 5 6
Focal sclerosis 1 3 4
Renal sarcoidosis 1 0 1
Lupus nephritis 1 10 11
Diabetic nephropathy 0 15 15
Focal glomerulonephritis 0 3 3
Acute post-streptococcal
glomerulonephritis 0 2 2
End-stage renal disease 0 1
Totals 33 118 151
a From Llach et al [110] with permission.
Abbreviation: N, number of patients.
significant. However, there are marked differences in this
incidence, ranging from 5 to 62%. The reason for such differ-
ences is not clear. One possibility, in light of current immuno-
logical advances, is that membranous nephropathy may include
different immunological entities, and some may be more prone
to develop RVT than others. Another possibility is that the
duration of the nephrotic syndrome and the persistence and
magnitude of hypoalbuminemia may have varied in these stud-
ies. Although membranous nephropathy has been associated
most commonly with RVT, membrano-proliferative glomerulo-
nephritis may be present also. For instance, in a recent pro-
spective study by Velasquez and Garcia of 19 nephrotic pa-
tients, of the 8 patients with membrano-proliferative glomeru-
lonephritis, 3 had RVT [116].
The pathogenic mechanism by which membranous nephrop-
athy leads to RVT is not known. Recently, it has been shown
that patients with nephrotic syndrome and membranous
nephropathy have a high incidence of other thromboembolic
phenomena in addition to RVT [18, 106]. Also, studies have
shown that greater hypercoagulability disturbances were noted
in patients with membranous nephropathy than in those ne-
phrotic patients with minimal change disease [119, 120]. A
recent study by Du et al of 44 nephrotic patients and membra-
nous nephropathy (14 with RVT) has shown levels of alpha-2
antiplasmin that were more elevated in patients with RVT than
in those without RVT [38]. Thus, it is possible that in patients
with membranous nephropathy, the hypercoagulability and
decreased fibrinolysis may be of greater magnitude than other
nephropathies. The second factor may be a reduction in plasma
volume, an important feature in all patients with the nephrotic
syndrome, but which, because of its long course, may be of
greater magnitude in membranous nephropathy than in other
nephropathies. This may result in a milieu more favorable for
the development of thrombosis. Theoretically, a sustained
reduction in blood volume could lead to a decreased venous
flow, favoring the development of RVT. In a previous study, we
have been impressed by the marked decrease in wash-out time
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Fig. 1. Schematic representation of pathogenetic factors leading to hypercoagulability, thromboembolic phenomena, and renal vein thrombosis
in nephrotic syndrome.
in the renal venograms in patients with membranous nephrop-
athy but without RVT [1]. Third, the nature of the immunolog-
ical injury may be of importance. A recent study investigating
the relationship between membranous nephropathy and RVT
separated a subpopulation of patients with both membranous
nephropathy and RVT by the presence of circulating immune
complexes, which were not present in the patients with mem-
branous nephropathy without RVT [1211. It is attractive to
speculate that such complexes may be a triggering factor in the
coagulation process. Recently, Berger and Yaneva demon-
strated the presence of Factor XII and pre-kallikrein in sub-
epithelial deposits in 29 patients with membranous nephropathy
[122]. Here it is tempting to relate the high incidence of RVT in
membranous nephropathy to the activation of Factor XII, a
factor at the crossroads of important proteolytic pathways.
In summary, the pathogenesis of RVT in patients with
membranous nephropathy may be multifarious. A general,
integrated scheme of the pathogenetic factors leading to RVT
and other thromboembolic complications is shown in Figure 1.
As we learn more about the pathogenesis of membranous
nephropathy, it is likely that we will learn more about RVT.
Furthermore, since the incidence of RVT in membranous
nephropathy is significant, investigation policies for patients
with nephrotic syndrome should include this point, and any
prospective study of patients with membranous nephropathy
should be done accordingly.
Clinically, the first description of RVT made by Rayer
emphasized the presence of flank pain and macroscopic
hematuria [123]. Consequently, early reports of RVT noted
these symptoms, and it was assumed that RVT always pre-
sented with an acute florid symptomatology. However, Har-
rison et al in 1956 described two groups of patients with RVT
[1241. The first group had a sudden onset of the above-
mentioned symptoms, while a second group was observed to
have only the nephrotic symptoms and absence of acute symp-
toms. Years later, Rosenmann et al in a study of 15 nephrotic
patients with RVT noted lack of symptoms in a majority of their
patients [125]. We have reviewed 74 cases of RVT over the last
decade prior to the above-mentioned prospective studies and
found that asymptomatic cases outnumbered symptomatic
cases, despite the fact that in many instances the renal
venograms were done because of symptoms such as acute flank
pain, pleuritic chest pain, rapid deterioration of renal function,
and worsening of proteinuria [106]. Our experience in the
prospective evaluation of 151 patients with nephrotic syndrome
demonstrates also the presence of two modes of clinical pre-
sentation: acute and chronic [109]. Acute RVT is usually
characterized by a recent episode of acute flank pain, macro-
scopic hematuria, flank tenderness at percussion, unilateral
roentgenographic abnormalities demonstrated by intravenous
pyelogram, and deterioration of renal function. Chronic RYT is
observed in the older patient usually. They are asymptomatic
and the intravenous pyelogram usually is within normal limits.
Of the first 33 nephrotic patients with renal vein thrombosis that
we studied, 29 were asymptomatic. The only clinical manifes-
tation in these patients on admission was peripheral edema.
The significant incidence of RVT, together with the lack of
symptomatology, raises the question of how to approach these
patients, both diagnostically and therapeutically. Asympto-
matic nephrotic patients with membranous nephropathy are at
high risk of developing RVT. Routine renal venography (unless
it is in the setting of prospective studies) may not be warranted
for two reasons. First, there are no data in the asymptomatic
patient that demonstrate the long-term ill effects of chronic
RVT. Second, renal venography is an invasive procedure, not
free of complications, and is reliable only in experienced hands.
The use of ultrasonography and computerized tomography have
yielded promising results in the diagnosis of RVT [126-427],
therefore, it is likely that in the near future these non-in-
vasive procedures may be done routinely in the asymptomatic
patients.
The presence of flank pain, macroscopic hematuria, pleuritic
chest pain, unexplained rapid deterioration of renal function, or
any other symptoms suggestive of thromboembolic phenomena
are reasonable indications for renal venography, given the
appropriate clinical setting.
Our experience on the course and treatment of renal vein
thrombosis in nephrotic patients is limited. In 1963, Kowal et al
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reviewed 65 patients with RVT [1281. Only 14 of these patients
were alive after two years of follow-up. Recurrent thromboem-
bolic phenomena were cited as the most common cause of
death. Later, Rosenmann et a! followed 11 of 15 nephrotic
patients with RVT over a period of 24 to 115 months. The
incidence of thromboembolic phenomena was high, and fatal in
seven patients. One or more episodes of pulmonary embolism
occurred in seven patients, and four had evidence suggestive of
repeated episodes of thrombosis involving the renal vein system
[125]. The three patients receiving anticoagulant therapy did
well, and no new episodes of pulmonary emboli developed.
These data suggest that the prognosis of nephrotic patients with
renal vein thrombosis is poor and is determined by the presence
or absence of recurrent thromboembolic complications. In
1970, Richet and Meyrier reviewed 112 cases reported in the
literature. Of the 112 patients, 72 had died (a 64% mortality rate)
[1291. Earlier, McCarthy et al estimated the average survival
period after the onset of thrombosis to be nine months [1051.
But, these data may not be representative of the present
prognosis of this condition. First, most of the earlier data about
the course and prognosis of renal vein thrombosis originally
came from autopsy studies and the mortality may have been
overestimated. Second, renal insufficiency secondary to renal
vein thrombosis was a common cause of death in these patients.
Today, dialysis therapy has reduced uremic death considerably.
Third, some patients reported in the early literature had the
acute mode of presentation, the prognosis for which may have
been different from the more common asymptomatic chronic
RVT described today. Nevertheless, the most common cause of
death in patients with RVT is still thromboembolic complica-
tions, most often pulmonary embolism.
Once the diagnosis of acute RVT is established, anticoagulant
therapy should be started immediately. Marked improvement of
renal function and other symptoms usually follow. Three of our
four patients with acute RVT had significant improvement in
creatinine clearance [1091. This finding substantiates the multi-
ple, isolated symptomatic cases reported previously [130—132].
Recanalization of the renal vein and, in some instances, a total
dissolution of the clot have been observed [132]. Heparin is the
initial therapy of choice, followed later by oral anticoagulation
(Warfarin). However, streptokinase and urokinase have shown
promising results in acute RVT and are worth investigating for
the therapy of acute RVT [133]. Andrassy and Ritz have
reported the beneficial effect of urokinase in a nephrotic patient
with acute RVT [1341.
Studies on the use of anticoagulants in asymptomatic patients
with chronic RVT are not available. Long-term survival has
been observed in isolated cases with RVT. Our experience with
chronic RVT suggests clinical efficacy of anticoagulant therapy
[109]. In our 29 patients with chronic RVT, none of the patients
on anticoagulant therapy had new thromboembolic episodes
and after two years of follow-up, they were alive. Furthermore,
there were six thromboembolic episodes in four of the 70
nephrotic patients without RVT who were not treated with
anticoagulants during the two-year follow-up period. However,
all of our patients with membranous nephropathy, with and
without RVT, experienced a similar mild progressive renal
function deterioration.
The duration of anticoagulation therapy is difficult to estab-
lish. Some investigators believe that a case can be made for
continuing anticoagulant therapy indefinitely [130]. Relapses
with new episodes of acute RVT have been observed after
cessation of therapy [135]. Thus, considering the lack of avail-
able data, it seems reasonable to maintain anticoagulant therapy
as long as the patient is nephrotic and has significant
hypoalbuminemia.
The high incidence of thromboembolic complications in pa-
tients with nephrotic syndrome questions the use of prophylac-
tic anticoagulant therapy in patients with RVT. Especially in
those patients with membranous nephropathy should this type
of therapy not be taken lightly since bleeding complications are
commonplace with long-term anticoagulation. Thus, prospec-
tive studies are necessary before definite recommendations can
be made. However, in nephrotic patients with previous throm-
boembolic complications who are at high risk (fractures, immo-
bilization, etc.), continuous anticoagulation therapy should be
considered.
Thromboembolic complications other than renal vein
thrombosis
The high cumulative risks of thromboembolic complications
in the nephrotic patient have been recognized only recently [14,
15, 18, 66, 100]. These complications have been observed
previously in the pulmonary arteries [136], axillary and subclav-
ian veins [137], femoral, coronary, and mesenteric arteries [138,
139]. However, the most common observation may be deep
vein thrombosis of the extremities. A summary of thromboem-
bolic complications studies is shown in Table 2. Thus, Andrassy
et al studied 84 nephrotic patients and observed 37 episodes of
thromboembolic complications in 30 patients during a period of
three years [18]. There were 23 episodes of deep vein
thrombosis, an incidence of 44%, and among the highest
number encountered in medical patients. Kanfer et a! observed
arterial and venous thrombosis in five out of eight children and
in 10 out of 29 adult nephrotic patients during a period of seven
years [15]. Though lower (27%), this is still a significant
incidence. Four other investigators have observed a 17% inci-
dence of mostly deep venous thrombosis [14, 66, 100, 1091. In
our prospective studies [109], 26 episodes of thromboembolic
complications other than RVT were noted in 151 nephrotic
patients (17%). Noteworthy is the finding that Pohi et a!
reported only one patient with RYT out of 54, but they
observed three episodes of thrombosis, an 8.5% incidence,
which is still high [112], and one can appreciate that the
incidence of thromboembolic complications does range from
8.5 to 44%. Peripheral venous thrombosis and pulmonary
embolism were the most frequent complications, but arterial
thrombosis occurred also.
In our prospective study, ventilation-perfusion lung scan was
performed in 94 nephrotic patients, 24 with and 70 without renal
vein thrombosis [109]. Asymptomatic perfusion defects in the
presence of normal chest x-rays were observed in 12 patients,
five with RVT, and seven without. Since no pulmonary angiog-
raphy was done in these patients, a definitive interpretation of
this defect is not possible. However, these data provide addi-
tional evidence that suggests a significant incidence of pulmo-
nary embolism in the nephrotic patients. Similar observations
have been made by Cameron et al, who observed seven out of
37 nephrotic patients (19%) with abnormal ventilation-perfusion
lung scan and only one with renal vein thrombosis [114].
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Clearly, there is a significant incidence of thromboembolic
phenomena other than RVT in nephrotic patients, but the
morbidity and mortality of these complications are not well
defined and prospective longitudinal studies must be done to
elucidate both the magnitude of this problem and the possible
prophylactic and therapeutic interventions needed by high-risk
patients.
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Oklahoma City, Oklahoma
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